Therefore, it can bepostulated that Tregs can impair antitumor immune responses in cancer patients.In addition to naturally occurring CD4+CD25+ Tregs, also IL-10 producing Tr1cells have been demonstrated to contribute to ineffective antitumor immuneresponses in cancer patients [88, 89]. Here, CD4 is linked to cancer.